A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) FDA Decision: Longboard Pharmaceuticals (LBPH)

The Phase 3 date for A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) by Longboard Pharmaceuticals (LBPH) is scheduled for August 21, 2026. This is the target date for the FDA to make a decision on this application.

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) is being developed by Longboard Pharmaceuticals for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) receives FDA approval, Longboard Pharmaceuticals (LBPH) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for LBPH on DilutionWatch at dilutionwatch.com/stock/LBPH.html.

You can view the full BiotechSign company profile for Longboard Pharmaceuticals (LBPH) at biotechsign.com/app/company/LBPH, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.